bosentan anhydrous has been researched along with lu 302872 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amberg, W; Hergenröder, S; Hillen, H; Jansen, R; Kettschau, G; Kling, A; Klinge, D; Raschack, M; Riechers, H; Unger, L | 1 |
| Aubert, JD; Juillerat-Jeanneret, L | 1 |
1 review(s) available for bosentan anhydrous and lu 302872
| Article | Year |
|---|---|
Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis.
Topics: Animals; Cardiovascular Diseases; Clinical Trials as Topic; Endothelin Receptor Antagonists; Fibrosis; Humans; Hypertension, Pulmonary; Neoplasms; Receptors, Endothelin | 2016 |
1 other study(ies) available for bosentan anhydrous and lu 302872
| Article | Year |
|---|---|
Discovery and synthesis of (S)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2- (4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic acid (LU 302872), a novel orally active mixed ET(A)/ET(B) receptor antagonist.
Topics: Administration, Oral; Animals; Blood Pressure; Bronchoconstriction; CHO Cells; Cricetinae; Endothelin Receptor Antagonists; Guinea Pigs; Male; Propionates; Pyrimidines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Stereoisomerism; Structure-Activity Relationship | 1999 |